Q-omics provides the consensus-scored CXXC5 profile across patient tissues and cancer cell-line models. CXXC5 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, CXXC5 is differentially expressed in 14, with the highest sampling consensus in THCA. Additionally, CXXC5 protein abundance shows 19,836 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, THCA, and GBM as cancer lineages where CXXC5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CXXC5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CXXC5 survival associations across molecular data types. CXXC5 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CXXC5 RNA expression–survival associations across cancer types. High CXXC5 expression shows unfavorable associations in UVM, MESO, KIRP, UCEC, LGG and LUSC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for CXXC5 RNA expression.
This table summarizes CXXC5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CXXC5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CXXC5 shows lower tumor expression in HNSC and KICH and higher tumor expression in THCA, COAD, BLCA and LUAD. The THCA box plot shows higher CXXC5 RNA expression in tumor versus normal tissue (log2 FC = +0.794, t-test p < 0.001).
This table shows molecular features associated with CXXC5 in patient tissues and cancer cell lines. In patient samples, CXXC5 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, CXXC5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BREAST and CNS.
